Monday’s Midday Movers: Novavax (NVAX), Stem Inc (STEM), Renesola (SOL), Sarepta Therapeutics (SRPT), Cameco (CCJ)

By Carrie Williams

So far Monday, May 3, NASDAQ is down -0.6% and the S&P is down -0.99%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Novavax (NVAXResearch Report), Stem Inc (STEMResearch Report), Renesola (SOLResearch Report), Sarepta Therapeutics (SRPTResearch Report) and Cameco (CCJResearch Report).

Novavax is down -14.74% in midday trading to $203.35. Shares opened today at $238.50. The company has a 52-week low of $16.41 and a 52-week high of $331.68. On the Street’s front, the average 12-month analyst price target for the stock is $323.00, marking a 35.43% potential upside from current levels. In a report issued on April 26, B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on NVAX, with a price target of $365.00, which implies an upside of 53% from current levels. Separately, on February 24, Ladenburg Thalmann’s Michael Higgins assigned a Hold rating to the stock . Over the last 3 months, the insider sentiment on Novavax has been negative based on 37 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Stem Inc is down -10.75% in midday trading to $23.50. Shares opened today at $26.33. The company has a 52-week low of $9.60 and a 52-week high of $51.49. In the last 30 days, insiders purchased $500K worth of STEM shares. Over the last 3 months, the insider sentiment on Stem Inc has been positive based on 4 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Renesola is down -8.45% in midday trading to $8.88. Shares opened today at $9.70. The company has a 52-week low of $0.91 and a 52-week high of $35.77. On the Street’s front, the average 12-month analyst price target for the stock is $14.75, marking a 52.06% potential upside from current levels. In a report issued on April 30, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating on SOL, with a price target of $15.00, which represents a potential upside of 55% from where the stock is currently trading.

See today’s analyst top recommended stocks >>

Sarepta Therapeutics is up 8.13% in midday trading to $77.04. Shares opened today at $71.25. The company has a 52-week low of $68.04 and a 52-week high of $181.83. On the Street’s front, the average 12-month analyst price target for the stock is $134.00, marking a 88.07% potential upside from current levels. In a report released today, William Blair analyst Tim Lugo maintained a Buy rating on SRPT. Separately, on April 26, Credit Suisse’s Judah Frommer initiated coverage with a Hold rating on the stock and has a price target of $72.00. Over the last 3 months, the insider sentiment on Sarepta Therapeutics has been negative based on 23 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Cameco is up 7.99% in midday trading to $18.38. Shares opened today at $17.02. The company has a 52-week low of $9.01 and a 52-week high of $19.71. On the Street’s front, the average 12-month analyst price target for the stock is $18.80, marking a 10.46% potential upside from current levels. In a report issued on April 13, Raymond James analyst Brian MacArthur reiterated a Buy rating on CCJ, with a price target of C$22.00, which represents a potential upside of 29% from where the stock is currently trading. Separately, on April 12, TD Securities’ Greg Barnes reiterated a Hold rating on the stock and has a price target of C$22.00. Over the last 3 months, the insider sentiment on Cameco has been negative based on 56 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>